POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
84 hedge funds and large institutions have $330M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 17 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
24% more funds holding
Funds holding: 68 → 84 (+16)
4% more capital invested
Capital invested by funds: $316M → $330M (+$14.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.6M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.81M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.99M |
| 2 |
Millennium Management
New York
|
-$4.69M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$3.66M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.58M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.32M |
PNT Hedge Fund Activity: Q2 2022 in Review
84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q2 2022, worth a combined $330M — up 4.5% from $316M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PNT positions and 17 closed out — a net gain of 16 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $26.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $4.99M sold.
- 84 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q2 2022, up from 68 in Q1 2022.
- Funds reported $330M of POINT Biopharma Global Inc. Common Stock stock for Q2 2022, up 4.5% quarter-over-quarter.
- 33 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q2 2022 and 17 closed out, a net change of +16 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q2 2022 was BlackRock, an estimated $26.7M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q2 2022 was Farallon Capital Management, an estimated $4.99M sold.
Based on aggregated 13F filings for Q2 2022.